Volume 25 | Issue 1 Fall 2015

Total Page:16

File Type:pdf, Size:1020Kb

Volume 25 | Issue 1 Fall 2015 Volume 25 | Issue 1 Fall 2015 ANNALS OF HEALTH LAW THE HEALTH POLICY AND LAW REVIEW OF LOYOLA UNIVERSITY CHICAGO SCHOOL OF LAW BEAZLEY INSTITUTE FOR HEALTH LAW AND POLICY EDITOR-IN-CHIEF Ryan B. Marcus PUBLICATIONS EDITOR TECHNICAL PRODUCTION EDITOR Morgan Carr Amy Michelau ADVANCE DIRECTIVE EDITOR ADVANCE DIRECTIVE EDITOR Jennifer Fenton Elise Robie MARKETING & COORDINATING EDITOR SYMPOSIUM EDITOR Sumaya Noush Sarah Kitlinski ANNALS SENIOR EDITORS James Flannery Christopher MacKenzie Holly McCurdy Joseph Willuweit MEMBERS Amanda Bast Fannie Fang Matthew Meidell Arielle Berens Alyse Fischer Christian Morgan Yi Bu Melvin Gaddy Dennis Pangindian Gilbert Carillo MaryKathryn Hurd Victor Ramos Sarah Costa Marika Iszczyszyn Chloe Schultz Lindsey Croasdale Erica Jewell Brittany Tomkies Erin Dine Alanna Kroeker Stephanie Toth Laura Doyen Kaitlin Lavin Xavier Vergara FACULTY ADVISORS Lawrence E. Singer, J.D., M.H.S.A. Director and Professor of Law, Beazley Institute for Health Law and Policy Loyola University Chicago School of Law John D. Blum, J.D., M.H.S. John J. Waldron Research Professor of Health Law Loyola University Chicago School of Law BUSINESS MANAGER Kristin Finn VOLUME 25, ISSUE 1 WINTER 2016 ANNALS OF HEALTH LAW Advance Directive THE STUDENT HEALTH POLICY AND LAW REVIEW OF LOYOLA UNIVERSITY CHICAGO SCHOOL OF LAW BRINGING YOU THE LATEST DEVELOPMENTS IN HEALTH LAW Beazley Institute for Health Law and Policy VOLUME 25, STUDENT ISSUE 1 FALL 2015 CONTENTS Editor’s Note Elise Robie and Jennifer Fenton ARTICLES Integrating Legal Aid in the Medicaid Managed Care Model Lindsey Croasdale .............................................................................................................. 1 ACOs Face the Demographics Dilemma of Managed Care Matthew Meidell .............................................................................................................. 14 A for Effort, I for Innovation: Hospital Readmissions Reduction Program and Its Positive Progress Xavier Vergara ................................................................................................................. 26 The Sunshine Act: Casting a Shadow on Health Care Innovation Alanna Kroeker ................................................................................................................ 36 Uniting All Interests: Law and Regulation Must Facilitate Pharmacogenomic Development Melvin Gaddy .................................................................................................................. 50 Analyzing Recent Trends in the Debate Over Gene Patents: United States and Australia Christian Morgan ............................................................................................................. 64 Drug Transparency Laws Will Not Drive Pharmaceutical Prices Down and Will Only Stifle Innovation Gilbert Carrillo ................................................................................................................. 77 Power to the People: How Medical Mobile Apps Are Increasing Patient Knowledge and Changing the Doctor-Patient Relationship Sarah Costa ...................................................................................................................... 87 Tough Love: Why Patients Should Change Physician Expectations Alyse Fischer ................................................................................................................... 97 ANNALS OF HEALTH LAW Advance Directive Editors’ Note The Annals of Health Law is proud to present the Fifteenth Issue of our online, student-written publication, Advance Directive. Advance Directive aims to support and encourage student scholarship in the area of health law and policy. In this vein, this issue explores the legal, regulatory, and economic challenges to innovation in health care. Healthcare innovation may conventionally be thought of as limited to issues related to technology, or development of new drugs and therapies or medical devices; however, healthcare innovation is decidedly broader, encompassing a vast array of different industries, providers, and legal frameworks. Here, the authors examine a variety of topics on the issue of healthcare innovation, ranging from the integration of social services into the traditional medical model to policies relating to increased transparency within the pharmaceutical industry. This issue begins with a discussion of the managed care model. Our first author examines how integration of legal aid into the managed care model could expand access to preventive care, thereby decreasing overall healthcare costs for individuals. Thereafter, another author critiques the financial success of managed care models, focusing on how demographics might negatively impact such success. Our discussion continues with the impact the Affordable Care Act (“ACA”) has had on innovation. First, one author considers the Hospital Readmissions Reduction Program, established in Section 3025 of the ACA, and argues that the Centers for Medicare & Medicaid Services successfully utilized this program to lower readmission rates, thus contributing to lower costs for healthcare organizations overall. The next article offers an author’s perspective on how the ACA has impacted innovation, with a specific focus on the influence of the Physician Payment Sunshine Act (“Sunshine Act”). The author examines how the Sunshine Act has possibly discouraged physician cooperation or participation in the development and advancement of the industry. Additionally, we navigate current debates within the pharmaceutical industry. One author discusses the role of genetics in the industry, arguing in favor of the use of genetic information to improve the effectiveness of medication. Another author discusses the patentability of genetic information. Finally, we end our focus on the pharmaceutical industry with an author who argues that drug transparency could potentially stifle innovation, rather than having the intended effect of decreasing cost. Lastly, we evaluate how innovation affects the traditional doctor-patient relationship. One author notes that medical mobile applications affect this traditional relationship by increasing consumer knowledge and participation in the health care process but argues that the Food & Drug Administration must increase regulation on these types of applications for them to remain safe and effective. We then discuss the ACA’s mandate that healthcare organizations meet a certain minimum level of patient satisfaction to receive Medicare funding. In this realm, our final author discusses the possibility that an increased focus on patient satisfaction, especially with an increasingly engaged consumer population might negatively impact the quality of care provided. We would like to thank Amy Michelau, our Technical Production Editor, because without her knowledge and commitment this Issue would not have been possible. We would like to give special thanks to our Annals Editor-in-Chief, Ryan Marcus, for his leadership and support. The Annals Executive Board Members, Sarah Kitlinski, Sumaya Noush, Amy Michelau, and Morgan Carr, and the Annals Senior Editors, Holly McCurdy, James Flannery, Joseph Willuweit, and Christopher MacKenzie provided invaluable editorial assistance with this Issue. The Annals members deserve special recognition for their thoughtful and topical articles and for editing the work of their peers. Lastly, we must thank the Beazley Institute for Health Law and Policy and our faculty advisors, Professor Lawrence Singer, Professor John Blum, and Kristin Finn for their guidance and support. We hope you enjoy our Fifteenth Issue of Advance Directive. Sincerely, Elise Robie Jennifer Fenton Advance Directive Editor Advance Directive Editor Annals of Health Law Annals of Health Law Loyola University Chicago School of Law Loyola University Chicago School of Law ANNALS OF HEALTH LAW Advance Directive VOLUME 25 FALL 2015 PAGES 1-13 Integrating Legal Aid in the Medicaid Managed Care Model Lindsey Croasdale* I. INTRODUCTION With federal and state budgets in crisis, government health care spending on the rise, the passage of the Patient Protection and Affordable Care Act (“PPACA”),1 and the moral commitment to provide affordable, high-quality health care to indigent populations, there has been a push in recent years for innovation in the public health care delivery system to contain the cost of providing quality care in the face of expanding access pressures.2 In particular, thirty-one states have expanded their Medicaid programs3 and many states have implemented a managed care delivery system, often administered by Managed Care Organizations (“MCOs”), into their Medicaid programs in an effort to make the delivery of care more efficient and to provide health care at a lower cost.4 Managed care is a type of health care delivery system in which state agencies contract with insurers who in turn contract with health care providers and medical facilities to provide care for patients at reduced costs.5 As of March 2015, there were 275 Medicaid MCOs nationwide.6 Managed Care Organizations open a window for innovation in the delivery * J.D. Candidate, May 2017, Loyola University Chicago School of Law. I thank Emily Benfer and John Blum for their gracious guidance and support. 1. See generally Patient Protection and Affordable Care Act, Pub. L. No. 111–148, 124 Stat. 119 (2010) (to be codified in scattered sections of 42 U.S.C.). 2. Managed Care, MEDICAID.GOV, http://www.medicaid.gov/medicaid-chip-program- information/by-topics/delivery-systems/managed-care/managed-care-site.html
Recommended publications
  • Download Open Letter
    1 Supply projections include vaccines produced by Pfizer/BioNTech, Moderna, AstraZeneca/Oxford, Johnson & Johnson, Novavax, and CureVac. Amanda Glassman J. Stephen Morrison Gary Edson Mark McClellan Executive Vice President, Senior Vice President and President, COVID Director, Duke-Margolis Center for Global Director, Global Health Collaborative Center for Health Policy, Development; CEO of CGD Policy Center, Center for Duke University Europe; and Senior Fellow Strategic and International John Bridgeland Studies CEO, COVID Krishna Udayakumar Rachel Silverman Collaborative Director, Duke Global Policy Fellow, Center for Katherine Bliss Health Innovation Center, Global Development Senior Fellow, Global Anjali Balakrishna Duke University Health Policy Center, Program Director, COVID Prashant Yadav Center for Strategic and Collaborative Michael Merson International Studies Senior Fellow, Center for Wolfgang Joklik Professor Global Development of Global Health, Duke Anna McCaffrey Global Health Institute, Fellow, Global Health Duke University Policy Center, Center for Strategic and International Studies Thomas Bollyky Helene Gayle William H. Frist Senior Fellow, Council on Foreign President and Chief Executive Former U.S. Senate Majority Relations Officer, The Chicago Community Leader Trust Scott Gottlieb Margaret (Peggy) Hamburg Amb [ret] Jimmy Kolker Resident Fellow, American Former Commissioner of the US Former Assistant Secretary, Enterprise Institute, and former Food and Drug Administration, Global Affairs, Department Health Commissioner
    [Show full text]
  • Participant Bios
    Sentinel Initiative Public Workshop Participant Biographies Mark McClellan, MD, PhD is director of the Engelberg Center for Health Care Reform and Leonard D. Schaeffer Chair in Health Policy Studies at the Brookings Institution. At the Center, his work focuses on promoting high-quality, innovative and affordable health care. A doctor and economist by training, he also has a highly distinguished record in public service and in academic research. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the Food and Drug Administration (FDA), where he developed and implemented major reforms in health policy. These include the Medicare prescription drug benefit, the FDA’s Critical Path Initiative, and public-private initiatives to develop better information on the quality and cost of care. Dr. McClellan chairs the FDA’s Reagan-Udall Foundation, is co-chair of the Quality Alliance Steering Committee, sits on the National Quality Forum’s Board of Directors, is a member of the Institute of Medicine, and is a research associate at the National Bureau of Economic Research. He previously served as a member of the President’s Council of Economic Advisers and senior director for health care policy at the White House, and was an associate professor of economics and medicine at Stanford University. Margaret Hamburg, MD is Commissioner of Food and Drugs, confirmed on May 18, 2009, by a unanimous Senate vote. The second woman to be nominated for the position, Dr. Hamburg is exceptionally qualified to serve with her training and experience as a medical doctor, scientist, and public health executive.
    [Show full text]
  • 067 Risky Business
    Risky Business: The Duque Government’s Approach to Peace in Colombia Latin America Report N°67 | 21 June 2018 Headquarters International Crisis Group Avenue Louise 149 • 1050 Brussels, Belgium Tel: +32 2 502 90 38 • Fax: +32 2 502 50 38 [email protected] Preventing War. Shaping Peace. Table of Contents Executive Summary ................................................................................................................... i I. Introduction ..................................................................................................................... 1 II. The FARC’s Transition to Civilian Life ............................................................................. 3 III. Rural Reform and Illicit Crop Substitution ...................................................................... 7 IV. Transitional Justice .......................................................................................................... 11 V. Security Threats ................................................................................................................ 14 VI. Conclusion ........................................................................................................................ 19 APPENDICES A. Colombian Presidential Run-off Results by Department ................................................ 21 B. Map of Colombia ............................................................................................................. 22 C. Acronyms .........................................................................................................................
    [Show full text]
  • Reducing Global COVID Vaccine Shortages
    Reducing Global COVID Vaccine Shortages: New Research and Recommendations for US Leadership April 15, 2021 Mark McClellan, MD, PhD Krishna Udayakumar, MD, MBA Michael Merson, MD Gary Edson, JD, MBA Authors Mark McClellan, Duke-Margolis Center for Michael Merson, Duke Global Health Health Policy Institute Krishna Udayakumar, Duke Global Health Gary Edson, COVID Collaborative Innovation Center Acknowledgements We thank Beth Boyer and Adam Kroetsch for assistance with our analyses and editing, and Morgan Romine and Patricia Green for editing and design support. We also thank Mark Dybul and Steve Morrison for helpful feedback on various aspects of this report. Disclosures Mark McClellan, MD, PhD, directs the Duke-Margolis Center for Health Policy, was Commissioner of the Food and Drug Administration from 2002-04 and Administrator of the Centers for Medicare and Medicaid Services from 2004-06. He is an independent director on the boards of Johnson & Johnson, Cigna, Alignment Healthcare, and PrognomIQ; co-chairs the Guiding Committee for the Health Care Payment Learning and Action Network; and receives fees for serving as an advisor for Arsenal Capital Partners, Blackstone Life Sciences, and MITRE. Krishna Udayakumar, MD, MBA, reports that the following organizations have provided research and operational support (funding and/or in-kind) through Duke-affiliated non-profit, Innovations in Healthcare, and/or Duke University in the past 12 months, or direct fees/honoraria, or represent equity holdings: Amazon, Amgen, AstraZeneca, Bayer, Bill and Melinda Gates Foundation, Grand Challenges Canada, McKinsey & Company, Medtronic, Pfizer, Pfizer Foundation, Takeda, USAID, Vynamic, WeberShandwick, World Economic Forum. Michael H Merson, MD, reports in the past 12 months fees/honoraria for serving as an advisor to Weber Shandwick and the National Basketball Association.
    [Show full text]
  • Risky Business Northern California Authority Northern California
    Municipal Pooling Municipal Pooling Authority Risky Business Northern California Authority Northern California How to Get Your Sleep Back… (Continued from Page 1) WINTER IS COMING—PREPARE Risky Business Fall Here are a few of the recommended ways to blunt the impact of COVID-19 2020 disruption on your sleep: YOUR HOME FOR THE COLD! • Get up at the same time each day – This is important even on the week- ends, so your brain and body get into a rhythm. Avoid sleeping in or napping Before the weather gets too cold, you should How to Get Your Sleep Back on Track in the afternoon. protect your house and family from the ele- • Get outside early – Natural sunlight tells our brain it is daytime so your brain ments. Here are some essential areas to check: can start preparing to help you perform your best and help you to wind down at the same time at night Roof COVID-19 has disrupted nearly every aspect of • Keep a routine – A routine will aid productivity, improve mood and expend the Look for missing shingles, cracked flashing, everyone’s life, and sleep is no exception. But be careful, says same amount of energy each day to best earn quality sleep onset at the same and broken overhanging tree limbs. UH clinical psychologist Carolyn Ievers-Landis, PhD -- the time each night. • Stay physically active – Exercising early in the day also helps to earn sleep Check the chimney for mortar deterioration irregular sleep schedules created by COVID-19 can have a at the same time each night.
    [Show full text]
  • Visionary's Dream Led to Risky Business Opaque Deals, Accounting Sleight of Hand Built an Energy Giant and Ensured Its Demise
    Visionary's Dream Led to Risky Business Opaque Deals, Accounting Sleight of Hand Built an Energy Giant and Ensured Its Demise By Peter Behr and April Witt Washington Post Staff Writers Sunday, July 28, 2002; Page A01 First of five articles For Vince Kaminski, the in-house risk-management genius, the fall of Enron Corp. began one day in June 1999. His boss told him that Enron President Jeffrey K. Skilling had an urgent task for Kaminski's team of financialanalysts. A few minutes later, Skilling surprised Kaminski by marching into his office to explain. Enron's investment in a risky Internet start-up called Rhythms NetConnections had jumped $300 million in value. Because of a securities restriction, Enron could not sell the stock immediately. But the company could and did count the paper gain as profit. Now Skilling had a way to hold on to that windfall if the tech boom collapsed and the stock dropped. Much later, Kaminski would come to see Skilling's command as a turning point, a moment in which the course of modern American business was fundamentally altered. At the time Kaminski found Skilling's idea merely incoherent, the task patently absurd. When Kaminski took the idea to his team -- world-class mathematicians who used arcane statistical models to analyze risk -- the room exploded in laughter. The plan was to create a private partnership in the Cayman Islands that would protect -- or hedge -- the Rhythms investment, locking in the gain. Ordinarily, Wall Street firms would provide such insurance, for a fee. But Rhythms was such a risky stock that no company would have touched the deal for a reasonable price.
    [Show full text]
  • JOSEPH P. NEWHOUSE January 27, 2020 Dr. Newhouse Is the John D
    JOSEPH P. NEWHOUSE January 27, 2020 Dr. Newhouse is the John D. MacArthur Professor of Health Policy and Management at Harvard University, Director of the Division of Health Policy Research and Education, and Director of the Interfaculty Initiative in Health Policy. He is a member of the faculties of the Harvard Kennedy School, the Harvard Medical School, the Harvard T.H. Chan School of Public Health, and the Faculty of Arts and Sciences, as well as a Research Associate of the National Bureau of Economic Research. He received B.A. and Ph.D. degrees in Economics from Harvard University and an honorary doctoral degree from the Pardee RAND Graduate School. Following his Bachelors degree, he was a Fulbright Scholar in Germany. Dr. Newhouse spent the first twenty years of his career at RAND, where he designed and directed the RAND Health Insurance Experiment. From 1981 to 1985 he was Head of the RAND Economics Department. In 1981 he became the founding editor of the Journal of Health Economics, which he edited for 30 years. He is a member of the editorial board of the American Journal of Health Economics and a past member of the editorial boards of the New England Journal of Medicine and the Journal of Economic Perspectives. In 1977 he was elected to the National Academy of Medicine (formerly the Institute of Medicine) and has served two terms on its governing Council. In 1995 he was elected a Fellow of the American Academy of Arts and Sciences. He is a past President of the Association for Health Services Research (AHSR), now AcademyHealth, of the International Health Economics Association, and was the inaugural President of the American Society of Health Economists.
    [Show full text]
  • Risky Business: Rethinking Lateral Partner Hiring
    Risky Business Rethinking Lateral Hiring February 2019 BROUGHT TO YOU BY Table of Contents About The Authors..................................................................................................................... 3 Methodology............................................................................................................................... 4 Introduction ................................................................................................................................ 5 Status Quo: Big Hires, Big Opportunities ................................................................................ 8 Everyone Hires ......................................................................................................................... 8 Hiring Laterally to Strengthen Existing Practice Areas .............................................................. 9 Lateral Hiring as a Way to Bring in New Clients and Support Growth ..................................... 10 Lateral Hiring to Support Expansion ....................................................................................... 12 Succession Planning .............................................................................................................. 14 Key Takeaways: Lateral Hiring Supports a Range of Goals for Law Firms ............................. 14 Risk, Reward, and Failure........................................................................................................ 15 The Cost of Acquiring Lateral Partners ..................................................................................
    [Show full text]
  • Risky Business Script Analysis
    Risky Business Screenplay Analysis Risky Business (1983) Wri$en and Directed by Paul Brickman Running 7me: 96min BASIC SCREENPLAY ANALYSIS PROTAGONIST: Joel Goodson, an 18 year old high school senior CHARACTERIZATION/MAIN MISBEHAVIOR: Naivety; guilt EXTERNAL GOAL: To get laid / To be accepted into Princeton INTERNAL GOAL: To sasfy his parents’ goals for his future / To make his own decisions MAIN DRAMATIC CONFLICT: Lana / Joel’s parents THEME: To get what you want out of life, remove guilt from the chances you take. CENTRAL DRAMATIC QUESTION: Can Joel overcome his naivety and guilt and blaze his own trail in the world? ENDING: Joel’s accepted into Princeton. ARC: Joel goes from a guilt-ridden, naive teenager, to a street-wise young man. STORY ENGINES ACT I As he drops them off at the airport for a week-long vacaon, Joel’s parents no7fy him of an admission interview for Princeton University. With his parents gone, Joel calls a pros7tute named Lana to his home and loses his virginity. Act II-A Lana steals Joel’s mother’s expensive Steuben glass egg, forcing Joel to find her. He brings her back to his home aer an altercaon turned car chase with her pimp, Guido. Joel is faced with a disaster when he sinks his father’s Porsche into Lake Michigan. Act II-B Joel and Lana turn Joel’s house into a brothel for one night to earn enough money to repair the Porsche. Forgeng Princeton, Joel is caught off guard when the admission’s officer shows up. Joel blows the interview, but does so guilt-free.
    [Show full text]
  • Mark B. Mcclellan, M.D., Ph.D. Duke University 100 Fuqua Drive Box 90120 Durham N.C
    CURRICULUM VITAE MARK B. MCCLELLAN, M.D., PH.D. DUKE UNIVERSITY 100 FUQUA DRIVE BOX 90120 DURHAM N.C. 27708 EDUCATION: 1993 Ph.D., Economics, Massachusetts Institute of Technology 1992 M.D., Harvard-MIT Division of Health Science and Technology, cum laude 1991 M.P.A., Regulatory Policy, Kennedy School of Government, Harvard University 1985 B.A., English/Biology, University of Texas, Austin, summa cum laude CLINICAL TRAINING: 1996 Diplomate, American Board of Internal Medicine 1993 – 1995 Resident in Internal Medicine, Department of Medicine, Brigham and Women's Hospital EMPLOYMENT: CURRENT POSTION 2015 - Present Director of the Duke-Margolis Center for Health Policy 2015 - Present Robert J. Margolis MD Professor of Business, Medicine and Health Policy 2015 - Present Faculty Member & Sr. Policy Advisor, University of Texas, Austin, Dell Medical School PREVIOUS POSITIONS 2007 – 2015 Senior Fellow in Economic Studies, Brookings Institution 2013 – 2015 Director, Initiatives on Value and Innovation in Health Care, Brookings Institution 2007 – 2013 Director, Engelberg Center for Health Care Reform, Brookings Institution 2006 – 2007 Visiting Senior Fellow, AEI-Brookings Joint Center for Regulatory Studies, American Enterprise Institute and the Brookings Institution 2004 – 2006 Administrator, Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services 2002 – 2004 Commissioner, U. S. Food and Drug Administration 2001 – 2002 Member, Council of Economic Advisers, and Senior Director for Health Care Policy, White House
    [Show full text]
  • Congress of the United States House of Representatives COMMITTEE on ENERGY and COMMERCE 2125 RAYBURN HOUSE OFFICE BUILDING WASHINGTON, DC 20515-6115
    FRANK PALLONE, JR., NEW JERSEY GREG WALDEN, OREGON CHAIRMAN RANKING MEMBER ONE HUNDRED SIXTEENTH CONGRESS Congress of the United States House of Representatives COMMITTEE ON ENERGY AND COMMERCE 2125 RAYBURN HOUSE OFFICE BUILDING WASHINGTON, DC 20515-6115 Majority (202) 225-2927 Minority (202) 225-3641 October 16, 2020 Mark McClellan, M.D., Ph.D. Founding Director Duke-Margolis Center for Health Policy Duke University 100 Fuqua Drive, Box 90120 Durham, NC 27708 Dear Dr. McClellan: Thank you for appearing before the Subcommittee on Oversight and Investigations on Wednesday, September 30, 2020, at the remote hearing entitled “Pathway to a Vaccine: Ensuring a Safe and Effective Vaccine People Will Trust.” We appreciate the time and effort you gave as a witness before the Subcommittee on Oversight and Investigations. Pursuant to Rule 3 of the Committee on Energy and Commerce, members are permitted to submit additional questions to the witnesses for their responses, which will be included in the hearing record. Attached are questions directed to you from me and other members of the Committee. In preparing your answers to these questions, please address your responses to the member who has submitted the questions using the Word document provided with this letter. To facilitate the publication of the hearing record, please submit your responses to these questions by no later than the close of business on Friday, October 30, 2020. As previously noted, your responses to the questions in this letter, as well as the responses from the other witnesses appearing at the hearing, will all be included in the hearing record.
    [Show full text]
  • The Honorable Orrin Hatch Senator of Utah Senate Finance Committee, Chairman 104 Hart Senate Office Building Washington, DC 20510
    The Honorable Orrin Hatch Senator of Utah Senate Finance Committee, Chairman 104 Hart Senate Office Building Washington, DC 20510 July 14, 2015 Dear Senator Hatch, While the undersigned often hold policy views which differ from those currently espoused by the Centers for Medicare & Medicaid Services (CMS), we write collectively to urge the confirmation of Andy Slavitt as CMS Administrator. Mr. Slavitt’s previous professional roles provide the required understanding of health markets and mechanisms, which CMS desperately needs at this time. Absent that perspective, the agency could naturally lean toward an overly prescriptive regulatory construct. Mr. Slavitt is well respected by both ideological camps and can play a constructive role in solving problems. CMS spends more tax payer money than any other federal government agency. The Administrator’s role requires a strong, seasoned executive able to make sound policy and operational judgments. Mr. Slavitt has demonstrated that ability in and out of government, in times of crisis and calm. Congress requires a relationship with the CMS Administrator characterized by civil dialog and candor. Each of us has worked with Mr. Slavitt and believes he is able to communicate and work with Congress constructively. Each of us has served either as Secretary of the United States Department of Health and Human Services, to whom the Administrator of CMS reports, or as Administrator of CMS (acting or confirmed). As former high-level officials at the Department of Health and Human Services, we are uniquely positioned to understand the Administrator’s role. Thank you for considering our views. Each of us is available to members of the Senate or their staffs who wish to have personal conversations related to this confirmation.
    [Show full text]